1490P Removal of TNF-Rs frees TNF-α’s anticancer activity alone or in combination chemo- or immunotherapy in advanced NSCLC von Bozkurt, M., Gökhan, D., Teomete, M., Turam, C., Florin, L., Ostrowski, A., Segal, R., Manax, V.

Volltext

PCN259 USING LONGITUDINAL PATIENT LEVEL DATA TO ASSESS THE VALUE OF NEW PANCREATIC CANCER TREATMENTS ON TOTAL HEALTH SPENDING von Goldberg, R., DelPriore, G., Kim, S., Korfin, M., Mandelson, M., Manax, V., Picozzi, V.

Volltext

253P Immunopheresis to remove soluble TNF receptors as a novel immunotherapy for patients with advanced breast cancer von Wysocki, P.J., Tomczak, P., Jankowski, T., Nowikiewicz, T., Manax, V., Florin, L., Segal, R., Djazouli, K.M., Bilgrami, S., Marleau, A., Ostrowski, A.

Volltext

Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer von Chiorean, EG, Von Hoff, DD, Tabernero, J, El-Maraghi, R, Ma, WW, Reni, M, Harris, M, Whorf, R, Liu, H, Li, JS, Manax, V, Romano, A, Lu, B, Goldstein, D

Volltext bestellen